Teneligliptin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 20 mg, 40mg
Reference Brands: Tenelia®, Teneza®, and Teneliget®(India & Japan/ Asia)
Category:
Diabetes
Teneligliptin is a DPP-4 inhibitor that increases incretin hormone levels, enhancing insulin secretion and reducing glucagon in a glucose-dependent manner. It improves glycemic control in type 2 diabetes with a low risk of hypoglycemia, is weight-neutral, and offers once-daily oral dosing—making it effective and patient-friendly.
Teneligliptin Tablets is available in Tablets
and strengths such as 20 mg, 40mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Teneligliptin Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Teneligliptin Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Teneligliptin, a DPP-4 inhibitor used for type 2 diabetes, is not approved by the U.S. FDA or the European Medicines Agency (EMA). It is currently not available in the US or EU markets due to the absence of regulatory submissions or market authorization. Teneligliptin is, however, widely approved in Asian countries like Japan and India. For companies seeking to register or introduce Teneligliptin in regulated markets, thorough clinical data, CTD dossiers, and compliance with ICH guidelines are essential. For regulatory consulting, dossier preparation, or global sourcing, visit PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing